Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

As the year comes to a close, the overall level of global mergers and acquisitions activity in 2024 is expected to be $3.5 ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

EUROPE’S Stoxx 600 index clocked its first weekly advance in three on Friday (Dec 27), boosted by advancing healthcare and ...

live cricket score india and australia Innovent Biologics Obtains Exclusive Rights to Two Cell Immunotherapy Products in Mainland China, Hong Kong and Macau Novo Nordisk Q1 2020: China grew 13%, ...

From politics to pop culture, climate to conflict, 2024 was a year of tumbling records … but not always for the best reasons.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

INR:3385. members of zerobaseone Innovent Biologics' Phase 3 clinical trial of Sintilimab as first-line treatment for advanced liver cancer reaches primary ...